Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The global drug gap.

M R Reich1

  • 1Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. reich@hsph.harvard.edu

Science (New York, N.Y.)
|February 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excess mortality among relocated institutionalized elderly after the Fukushima nuclear disaster.

Public health·2012
Same author

The global drug gap: policy implications for microbicides.

AIDS (London, England)·2001
Same author

Schistosoma haematobium.

The New England journal of medicine·2001
Same author

Abortion trends in Japan, 1975-95.

Studies in family planning·2001
Same author

Public-private partnerships for public health.

Nature medicine·2000
Same author

Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration.

Journal of the American Veterinary Medical Association·2000

Global drug access inequities persist due to market failures and income gaps. Addressing this requires policies combining research subsidies, financial incentives, and institutional improvements for essential, new, and future medicines.

Area of Science:

  • Global Health
  • Pharmaceutical Policy
  • Health Economics

Background:

  • Significant global inequities exist in access to pharmaceutical products between high-income and low-income countries.
  • These disparities stem from a combination of market failures, government shortcomings, and substantial income differentials.
  • The global drug gap affects access to essential, new, and yet-to-be-developed medicines.

Purpose of the Study:

  • To outline policy recommendations for addressing the global drug gap.
  • To propose a multi-faceted policy approach combining different intervention types.
  • To balance the need for research and development incentives with equitable access to medicines.

Main Methods:

  • Policy analysis framework integrating push, pull, and process approaches.
Keywords:
Health Care and Public Health

Related Experiment Videos

  • Review of existing literature on pharmaceutical access and innovation.
  • Conceptualization of integrated policy solutions.

    • Main Results:

    • A comprehensive policy framework is necessary, not a single solution.
    • Policies must address distinct categories of pharmaceutical products (essential, new, future).
    • Integration of push (subsidies), pull (market guarantees), and process (institutional capacity) strategies is recommended.

    Conclusions:

    • Addressing global drug access inequities requires a combination of targeted R&D support and market-based incentives.
    • Strengthening institutional capacity is crucial for effective policy implementation.
    • Balancing innovation incentives with equitable access is achievable through strategic policy design.